Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Durect Corp (DRRX)

Durect Corp (DRRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,075
  • Shares Outstanding, K 31,039
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -27,620 K
  • 60-Month Beta 1.14
  • Price/Sales 5.66
  • Price/Cash Flow N/A
  • Price/Book 9.31
Trade DRRX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -11.47%)
  • Historical Volatility 88.40%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 740.40% on 05/16/24
  • IV Low 0.00% on 09/18/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 100
  • Volume Avg (30-Day) 50
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 3,367
  • Open Int (30-Day) 3,002

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.29
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +52.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +20.54%
on 08/19/24
1.6550 -18.43%
on 09/05/24
+0.2300 (+20.54%)
since 08/16/24
3-Month
1.1000 +22.73%
on 08/16/24
1.7400 -22.41%
on 07/24/24
-0.2400 (-15.09%)
since 06/18/24
52-Week
0.4703 +187.05%
on 11/10/23
3.1400 -57.01%
on 11/02/23
-1.4000 (-50.91%)
since 09/18/23

Most Recent Stories

More News
Durect: Q2 Earnings Snapshot

Durect: Q2 Earnings Snapshot

DRRX : 1.3500 (-4.93%)
Durect: Q1 Earnings Snapshot

Durect: Q1 Earnings Snapshot

DRRX : 1.3500 (-4.93%)
Durect: Q4 Earnings Snapshot

Durect: Q4 Earnings Snapshot

DRRX : 1.3500 (-4.93%)
Durect: Q3 Earnings Snapshot

Durect: Q3 Earnings Snapshot

DRRX : 1.3500 (-4.93%)
DURECT Corporation Announces Presentations in Upcoming Investor Conferences

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 1.3500 (-4.93%)
Durect: Q2 Earnings Snapshot

Durect: Q2 Earnings Snapshot

DRRX : 1.3500 (-4.93%)
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update....

DRRX : 1.3500 (-4.93%)
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 1.3500 (-4.93%)
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the...

DRRX : 1.3500 (-4.93%)
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and...

DRRX : 1.3500 (-4.93%)

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

3rd Resistance Point 1.7400
2nd Resistance Point 1.6500
1st Resistance Point 1.5000
Last Price 1.3500
1st Support Level 1.2600
2nd Support Level 1.1700
3rd Support Level 1.0200

See More

52-Week High 3.1400
Fibonacci 61.8% 2.1202
Fibonacci 50% 1.8052
Fibonacci 38.2% 1.4901
Last Price 1.3500
52-Week Low 0.4703

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar